Form 4: Leap Therapeutics' Chief Scientific Officer, Jason Baum, Acquires 85,000 Stock Options

Jason Baum, Chief Scientific Officer of Leap Therapeutics, acquired 85,000 stock options on October 2, 2024, according to a Form 4 filing with the SEC.

Summary

• Jason Baum, the Chief Scientific Officer of Leap Therapeutics, Inc., was granted 85,000 employee stock options on October 2, 2024.
• The options have an exercise price of $2.45.
• The options were granted under Leap's 2022 Equity Incentive Plan.
• The options vest in 36 equal monthly installments, starting one month after the grant date, contingent upon continued employment with the company.
• The options expire on October 2, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future, but it's not a major event.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation component for executives in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
• The vesting schedule of 36 months is fairly standard for these types of grants.

Stakeholder Impact

• Shareholders may view the option grant as a positive sign, aligning management's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates